-
Sell-Side Analysts See Upside Potential In Zynerba
Tuesday, November 13, 2018 - 3:19pm | 387Read More...Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) have dropped by about 12 percent since the company reported third-quarter results Nov. 8. Analysts at HC Wainwright and Canaccord Genuity consider the sell-off an overreaction and issued positive updates on the company this week. The Analysts HC...
-
Analyst: Nektar Has A Handful Of Milestones Ahead In 2018
Monday, November 13, 2017 - 12:49pm | 556Read More...Nektar Therapeutics (NASDAQ: NKTR) shares are soaring Monday to new 15-year highs after the company reported more positive data on its therapeutic cancer treatment candidate NKTR-214. Full Phase-I PIVOT-2 dose-escalation results indicated promising effects from Nektar’s wholly-owned...
-
UPDATE: MLV & Co Initiates Coverage On Ultragenyx Pharmaceutical On Positive Outlook
Tuesday, March 31, 2015 - 7:47am | 145Read More...In a report published Tuesday, MLV & Co analyst Arlinda Lee initiated coverage on Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) with a Buy rating and $79.00 price target. In the report, MLV & Co noted, "With four product candidates in the clinic for six debilitating and life-threatening...
-
MannKind's Accounting Is 'Murky,' MLV Analyst Says
Wednesday, February 25, 2015 - 11:15am | 331Read More...MLV & Co. commented on MannKind Corporation (NASDAQ: MNKD) following the company’s Q4 earnings report. The firm maintained a Hold rating and $7 price target. Analyst Arlinda Lee noted that the company reported in line results but looked for data on NRx and TRx for Afrezza, as well...
-
MLV & Co Raises Price Target On Xencor On Attractive Investment Opportunity
Wednesday, January 28, 2015 - 10:51am | 105Read More...In a report published Wednesday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Xencor (NASDAQ: XNCR), and raised the price target from $18.00 to $22.00. In the report, MLV & Co noted, “After reviewing IgG4-Related Disease (IgG4-RD) and XmAb5871 literature, we are more confident in...
-
UPDATE: MLV & Co Raises PT On Halozyme Therapeutics On Promising Start To 2015
Thursday, January 8, 2015 - 10:36am | 200Read More...In a report published Thursday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Halozyme Therapeutics (NASDAQ: HALO), and raised the price target from $12.00 to $15.00. In the report, MLV & Co noted, “During its analyst day, HALO announced interim Ph2 PEGPH20 pancreatic cancer...
-
UPDATE: MLV Initiates Coverage On Agios Pharmaceuticals
Thursday, December 4, 2014 - 11:22am | 296Read More...MLV initiated coverage on Agios Pharmaceuticals Inc (NASDAQ: AGIO) with a Buy rating and $123 price target. Analyst Arlinda Lee noted that “AGIO’s integrated metabolome and genome approach identifies novel targets and has produced 3 drug candidates targeting metabolic dysfunction in...
-
UPDATE: MLV & Co. Initiates Coverage On Sorrento Therapeutics On Good Cynviloq Potential
Thursday, June 19, 2014 - 7:57am | 110Read More...In a report published Thursday, MLV & Co. analyst Arlinda Lee initiated coverage on Sorrento Therapeutics (NASDAQ: SRNE) with a Buy rating and $9.00 price target. In the report, MLV & Co. noted, “We are initiating coverage of SRNE with a Buy rating and $9 price target. We believe that lead...
